Revista de la CEPAL no.95

La emergencia de las multilatinas / Javier Santiso .-- La nueva pobreza urbana: dinámica global, regional y argentina en las últimas dos décadas / Gabriel Kessler y María Mercedes Di Virgilio .-- La regulación económica como complemento de las licitaciones en las concesiones de obras públicas / Eugenio Rivera .-- La relación entre crisis cambiarias y bancarias en países emergentes: los problemas de información y expectativas / Daniel Sotelsek y Lilianne Pavón .-- La paradoja del crecimiento lento de México / Carlos Ibarra .-- Globalización y desarrollo regional: evolución económica de las regiones chilenas, 1990-2002 / Juan Carlos Ramírez J. e Iván Silva Lira .-- Efectos de protección financiera del sistema de salud pública y del seguro privado en Brasil / Antônio M. Bós y Hugh R. Waters .-- Impactos de la discriminación por género sobre la pobreza brasileña / Rosycler Cristina Santos Simão y Sandro Eduardo Monsueto .-- Consolidación bancaria y concentración del crédito en Brasil (1995-2004) / Daniel B. de Castro Almeida y Frederico G. Jayme Jr. .-- Orientaciones para los colaboradores de la Revista de la cepal .-- Publicaciones recientes de la cepal.

Notas de Población Vol.39 N° 95

Incluye bibliografía

O Decreto Nº 39.902/95 eAs Reformas Administrativas da

As primeiras medidas tomadas no Governo do Sr. Mário Covas, referentes à Educação no Estado de São Paulo, estão contidas no Decreto. 39.902/95, que extinguiu as Divisões Regionais de Ensino. Este trabalho propõe-se a analisar tais mudanças no sentido de contribuir para uma maior compreensão das mesmas, bem como, descrever algumas atividades desenvolvidas pela Coordenadoria de Ensino do Interior (CEI) que tive-ram como objetivo facilitar a implantação de tais medidas.

Structural refinement, optical and electrical properties of [Ba1-x Sm-2x/3](Zr0.05Ti0.95)O-3 ceramics

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Structural refinement, optical and ferroelectric properties of microcrystalline Ba(Zr0.05Ti0.95)O-3 perovskite

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

O equilíbrio econômico-financeiro dos contratos de concessão de rodovias federais e estaduais sob a égide da Lei 8.987/95

Pós-graduação em Direito - FCHS

Alessi 95 and the short-period Cepheid SU Cassiopeiae

The parameters for the newly discovered open cluster Alessi 95 are established on the basis of available photometric and spectroscopic data, in conjunction with new observations. Colour excesses for spectroscopically observed B- and A-type stars near SU Cas follow a reddening relation described by E(U-B)/E(B-V) = 0.83 + 0.02E(B-V), implying a value of R=AV/E(B-V) ? 2.8 for the associated dust. Alessi 95 has a mean reddening of E(B-V)(B0) = 0.35 +/- 0.02 s.e., an intrinsic distance modulus of V0-MV= 8.16 +/- 0.04 s.e. (+/- 0.21 s.d.), d= 429 +/- 8 pc, and an estimated age of 108.2 yr from zero-age main sequence (ZAMS) fitting of available UBV, CCD BV, NOMAD, and Two Micron All Sky Survey JHKs observations of cluster stars. SU Cas is a likely cluster member, with an inferred space reddening of E(B-V) = 0.33 +/- 0.02 and a luminosity of < MV >=-3.15 +/- 0.07 s.e., consistent with overtone pulsation (PFM= 2.75 d), as also implied by the Cepheids light-curve parameters, rate of period increase and Hipparcos parallaxes for cluster stars. There is excellent agreement of the distance estimates for SU Cas inferred from cluster ZAMS fitting, its pulsation parallax derived from the infrared surface brightness technique and Hipparcos parallaxes, which all agree to within a few per cent.

Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95

PURPOSE: To compare adjuvant dose-intensive epirubicin and cyclophosphamide chemotherapy administered with filgrastim and progenitor cell support (DI-EC) with standard-dose anthracycline-based chemotherapy (SD-CT) for patients with early-stage breast cancer and a high risk of relapse, defined as stage II disease with 10 or more positive axillary nodes; or an estrogen receptor-negative or stage III tumor with five or more positive axillary nodes. PATIENTS AND METHODS: Three hundred forty-four patients were randomized after surgery to receive seven cycles of SD-CT over 22 weeks, or three cycles of DI-EC (epirubicin 200 mg/m2 plus cyclophosphamide 4 gm/m2 with filgrastim and progenitor cell support) over 6 weeks. All patients were assigned tamoxifen at the completion of chemotherapy. The primary end point was disease-free survival (DFS). RESULTS: After a median follow-up of 5.8 years (range, 3 to 8.4 years), 188 DFS events had occurred (DI-EC, 86 events; SD-CT, 102 events). The 5-year DFS was 52% for DI-EC and 43% for SD-CT, with hazard ratio of DI-EC compared with SD-CT of 0.77 (95% CI, 0.58 to 1.02; P = .07). The 5-year overall survival was 70% for DI-EC and 61% for SD-CT, with a hazard ratio of 0.79 (95% CI, 0.56 to 1.11; P = .17). There were eight cases (5%) of anthracycline-induced cardiomyopathy (two fatal) among those who received DI-EC. Women with hormone receptor-positive tumors benefited significantly from DI-EC. CONCLUSION: There was a trend in favor of DI-EC with respect to disease-free survival. A larger trial or meta-analysis will be required to reveal the true effect of dose-intensive therapy.

The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas

A multicenter trial was performed to confirm the therapeutic efficacy and the toxicity profile of the combination of cladribine, cyclophosphamide and prednisone in low-grade non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Twenty-three adults with previously treated (61%) or untreated (39%) NHL International Working Formulation A or Binet B and C CLL were administered cladribine 0.1 mg/kg/day as a subcutaneous bolus for 5 days, intravenous cyclophosphamide 500 mg/m2 on day 1, and oral prednisone 40 mg/m2 on days 1-5, every 4 weeks. Unexpected early hematological toxicities led to dose modifications for pretreated patients who received cladribine for 3 days only up to a maximum of five courses. Responses were observed in 75%, with 7 patients obtaining a complete clinical and hematological response. Median duration of complete response was 9 months. Median time to progression or relapse was 31 months. Myelosuppression and infections were dose limiting whereas posttreatment complications, including fatalities, resulted from infections. Median overall survival time from trial entry was 60 months. Activity of the combination of cladribine, cyclophosphamide and prednisone was confirmed. However, in the specific setting of a multicenter trial, unexpected fatal infectious episodes occurred in pretreated patients. Great caution is thus required in these susceptible patients and the routine use of corticosteroids should probably be abandoned.